Skip to main content
Erschienen in:

30.11.2022 | short review

Total neoadjuvant therapy in rectal cancer

verfasst von: Dr. Gudrun Piringer, MSc, Prim. Univ.-Doz. Dr. Alexander De Vries

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Summary

Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective summary viewed from different perspectives of the available literature of previous milestones that have been achieved in the treatment of locally advanced rectal cancer, of current recommendations, and of future perspectives.
Literatur
1.
Zurück zum Zitat Enker WE, Laffer UT, Block GE. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg. 1979;190(3):350–60.PubMedPubMedCentralCrossRef Enker WE, Laffer UT, Block GE. Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg. 1979;190(3):350–60.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg. 1983;198(2):159–63.PubMedPubMedCentralCrossRef Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg. 1983;198(2):159–63.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA. 1988;259(24):3571–8.PubMedCrossRef Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA. 1988;259(24):3571–8.PubMedCrossRef
5.
Zurück zum Zitat Cedermark B, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.PubMedCrossRef Cedermark B, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.PubMedCrossRef
6.
Zurück zum Zitat Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRef Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRef
7.
Zurück zum Zitat Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRef Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRef
8.
Zurück zum Zitat Brown G, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91(1):23–9.PubMedPubMedCentralCrossRef Brown G, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91(1):23–9.PubMedPubMedCentralCrossRef
9.
10.
Zurück zum Zitat Beets-Tan RG, Beets GL. Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging. 2011;33(5):1012–9.PubMedCrossRef Beets-Tan RG, Beets GL. Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging. 2011;33(5):1012–9.PubMedCrossRef
11.
Zurück zum Zitat Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis. 2003;5(5):392–5.PubMedCrossRef Beets-Tan RG. MRI in rectal cancer: the T stage and circumferential resection margin. Colorectal Dis. 2003;5(5):392–5.PubMedCrossRef
12.
Zurück zum Zitat Maughan NJ, Quirke P. Modern management of colorectal cancer—a pathologist’s view. Scand J Surg. 2003;92(1):11–9.PubMedCrossRef Maughan NJ, Quirke P. Modern management of colorectal cancer—a pathologist’s view. Scand J Surg. 2003;92(1):11–9.PubMedCrossRef
13.
Zurück zum Zitat Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.PubMedCrossRef Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.PubMedCrossRef
14.
Zurück zum Zitat Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.PubMedCrossRef Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.PubMedCrossRef
15.
Zurück zum Zitat Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol. 2003;4(11):695–702.PubMedCrossRef Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol. 2003;4(11):695–702.PubMedCrossRef
16.
Zurück zum Zitat van den Broek CB, et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014;40(12):1789–96.PubMedCrossRef van den Broek CB, et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014;40(12):1789–96.PubMedCrossRef
17.
Zurück zum Zitat van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRef van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRef
18.
Zurück zum Zitat Breugom AJ, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.PubMedCrossRef Breugom AJ, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.PubMedCrossRef
19.
Zurück zum Zitat Bosset J‑F, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.PubMedCrossRef Bosset J‑F, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.PubMedCrossRef
20.
Zurück zum Zitat Schmoll HJ, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17–29.PubMedCrossRef Schmoll HJ, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17–29.PubMedCrossRef
21.
Zurück zum Zitat Rödel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.PubMedCrossRef Rödel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.PubMedCrossRef
22.
Zurück zum Zitat Kim TW, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011;81(4):1025–31.PubMedCrossRef Kim TW, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011;81(4):1025–31.PubMedCrossRef
23.
Zurück zum Zitat Marijnen CA, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(5):1311–20.PubMedCrossRef Marijnen CA, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(5):1311–20.PubMedCrossRef
24.
Zurück zum Zitat Strassburg J, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18(10):2790–9.PubMedCrossRef Strassburg J, et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann Surg Oncol. 2011;18(10):2790–9.PubMedCrossRef
25.
Zurück zum Zitat Junginger T, et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir. 2006;131(4):275–84.PubMedCrossRef Junginger T, et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir. 2006;131(4):275–84.PubMedCrossRef
26.
Zurück zum Zitat Kreis ME, et al. Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation—interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg. 2016;20(1):25–32. discussion 32–33.PubMedCrossRef Kreis ME, et al. Use of preoperative magnetic resonance imaging to select patients with rectal cancer for neoadjuvant chemoradiation—interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg. 2016;20(1):25–32. discussion 32–33.PubMedCrossRef
27.
Zurück zum Zitat Ruppert R, et al. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM rectal cancer trial. Br J Surg. 2018;105(11):1519–29.PubMedCrossRef Ruppert R, et al. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM rectal cancer trial. Br J Surg. 2018;105(11):1519–29.PubMedCrossRef
28.
Zurück zum Zitat Ruppert R, et al. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg. 2020;231(4):413–425.e2.PubMedCrossRef Ruppert R, et al. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg. 2020;231(4):413–425.e2.PubMedCrossRef
29.
Zurück zum Zitat Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef
30.
Zurück zum Zitat Petrelli F, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5‑year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017;8(1):39–48.PubMedPubMedCentralCrossRef Petrelli F, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5‑year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017;8(1):39–48.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Sargent D, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X‑ACT, PETACC‑3, C‑06, C‑07 and C89803. Eur J Cancer. 2011;47(7):990–6.PubMedPubMedCentralCrossRef Sargent D, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X‑ACT, PETACC‑3, C‑06, C‑07 and C89803. Eur J Cancer. 2011;47(7):990–6.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Merkel S, et al. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis. 2011;13(2):123–31.PubMedCrossRef Merkel S, et al. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis. 2011;13(2):123–31.PubMedCrossRef
34.
Zurück zum Zitat Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.PubMedCrossRef Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.PubMedCrossRef
35.
Zurück zum Zitat Deng HY, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J Cardiothorac Surg. 2017;51(3):421–31.PubMed Deng HY, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J Cardiothorac Surg. 2017;51(3):421–31.PubMed
36.
Zurück zum Zitat Wiśniowska K, et al. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016;42(12):1859–65.PubMedCrossRef Wiśniowska K, et al. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016;42(12):1859–65.PubMedCrossRef
37.
Zurück zum Zitat Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.PubMedCrossRef Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.PubMedCrossRef
38.
Zurück zum Zitat Rödel C, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.PubMedCrossRef Rödel C, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.PubMedCrossRef
39.
Zurück zum Zitat Bittner R, et al. Report on the workshop “workflow rectal cancer II” in Burghausen. Zentralbl Chir. 2007;132(2):95–8.PubMedCrossRef Bittner R, et al. Report on the workshop “workflow rectal cancer II” in Burghausen. Zentralbl Chir. 2007;132(2):95–8.PubMedCrossRef
40.
Zurück zum Zitat Buhr HJ, et al. Clinical pathway (workflow) for diagnostic, therapy and follow-up in patients with rectal cancer. Zentralbl Chir. 2006;131(4):285–97.PubMedCrossRef Buhr HJ, et al. Clinical pathway (workflow) for diagnostic, therapy and follow-up in patients with rectal cancer. Zentralbl Chir. 2006;131(4):285–97.PubMedCrossRef
41.
Zurück zum Zitat Roxburgh CSD, et al. Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes. Colorectal Dis. 2019;21(10):1140–50.PubMedPubMedCentralCrossRef Roxburgh CSD, et al. Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes. Colorectal Dis. 2019;21(10):1140–50.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Conroy T, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.PubMedCrossRef Conroy T, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.PubMedCrossRef
43.
Zurück zum Zitat Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.PubMedCrossRef Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.PubMedCrossRef
44.
Zurück zum Zitat Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56.PubMedCrossRef Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56.PubMedCrossRef
45.
Zurück zum Zitat Fokas E, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.PubMedCrossRef Fokas E, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.PubMedCrossRef
47.
Zurück zum Zitat Benson AB, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901.PubMedCrossRef Benson AB, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901.PubMedCrossRef
49.
Zurück zum Zitat Smith JJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3‑year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.PubMedPubMedCentralCrossRef Smith JJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3‑year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Ludmir EB, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123(9):1497–506.PubMedCrossRef Ludmir EB, et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123(9):1497–506.PubMedCrossRef
51.
Zurück zum Zitat Wang X, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial. Radiother Oncol. 2018;129(2):300–5.PubMedCrossRef Wang X, et al. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial. Radiother Oncol. 2018;129(2):300–5.PubMedCrossRef
52.
Zurück zum Zitat Riesco-Martinez MC, et al. Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of randomized trials. Cancers (Basel). 2020;12(12):3655.PubMedCrossRef Riesco-Martinez MC, et al. Impact of total neoadjuvant therapy vs. standard chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of randomized trials. Cancers (Basel). 2020;12(12):3655.PubMedCrossRef
53.
Zurück zum Zitat Liu S, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1555–e66.PubMedPubMedCentralCrossRef Liu S, et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist. 2021;26(9):e1555–e66.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Valadão M, et al. Do we have to treat all T3 rectal cancer the same way? Clin Colorectal Cancer. 2020;19(4):231–5.PubMedCrossRef Valadão M, et al. Do we have to treat all T3 rectal cancer the same way? Clin Colorectal Cancer. 2020;19(4):231–5.PubMedCrossRef
55.
Zurück zum Zitat Lee JB, et al. Role of preoperative chemoradiotherapy in clinical stage II/III rectal cancer patients undergoing total mesorectal excision: a retrospective propensity score analysis. Front Oncol. 2020;10:609313.PubMedCrossRef Lee JB, et al. Role of preoperative chemoradiotherapy in clinical stage II/III rectal cancer patients undergoing total mesorectal excision: a retrospective propensity score analysis. Front Oncol. 2020;10:609313.PubMedCrossRef
56.
Zurück zum Zitat Bujko K, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42.PubMedCrossRef Bujko K, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–42.PubMedCrossRef
57.
Zurück zum Zitat Ciseł B, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–303.PubMedCrossRef Ciseł B, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298–303.PubMedCrossRef
58.
Zurück zum Zitat Benson AB, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15.PubMedCrossRef Benson AB, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–15.PubMedCrossRef
59.
Zurück zum Zitat Harrison JD, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143(4):389–94.PubMedCrossRef Harrison JD, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143(4):389–94.PubMedCrossRef
60.
Zurück zum Zitat Breugom AJ, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.PubMedCrossRef Breugom AJ, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.PubMedCrossRef
61.
Zurück zum Zitat Goodman KA. Definitive chemoradiotherapy (“watch-and-wait” approach). Semin Radiat Oncol. 2016;26(3):205–10.PubMedCrossRef Goodman KA. Definitive chemoradiotherapy (“watch-and-wait” approach). Semin Radiat Oncol. 2016;26(3):205–10.PubMedCrossRef
62.
Zurück zum Zitat Lopez-Campos F, et al. Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol. 2020;26(29):4218–39.PubMedPubMedCentralCrossRef Lopez-Campos F, et al. Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol. 2020;26(29):4218–39.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Xu Q, et al. MRI evaluation of complete response of locally advanced rectal cancer after neoadjuvant therapy: current status and future trends. Cancer Manag Res. 2021;13:4317–28.PubMedPubMedCentralCrossRef Xu Q, et al. MRI evaluation of complete response of locally advanced rectal cancer after neoadjuvant therapy: current status and future trends. Cancer Manag Res. 2021;13:4317–28.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Dattani M, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.PubMedCrossRef Dattani M, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.PubMedCrossRef
65.
Zurück zum Zitat Habr-Gama A, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 717–8.PubMedPubMedCentralCrossRef Habr-Gama A, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 717–8.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Habr-Gama A, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12):1692–8.PubMedCrossRef Habr-Gama A, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53(12):1692–8.PubMedCrossRef
67.
Zurück zum Zitat Glynne-Jones R, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40.PubMedCrossRef Glynne-Jones R, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40.PubMedCrossRef
68.
Zurück zum Zitat Yu M, et al. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37(4):855–68.PubMedCrossRef Yu M, et al. Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses. Int J Colorectal Dis. 2022;37(4):855–68.PubMedCrossRef
69.
Zurück zum Zitat Petrelli F, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.PubMedCrossRef Petrelli F, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64.PubMedCrossRef
70.
Zurück zum Zitat Deidda S, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative Chemoradiation. JAMA Surg. 2021;156(12):1141–9.PubMedPubMedCentralCrossRef Deidda S, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative Chemoradiation. JAMA Surg. 2021;156(12):1141–9.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Dizdarevic E, Hansen TF, Jakobsen A. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. Cancers (Basel). 2022;14(9):2252.PubMedCrossRef Dizdarevic E, Hansen TF, Jakobsen A. The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. Cancers (Basel). 2022;14(9):2252.PubMedCrossRef
72.
Zurück zum Zitat Murahashi S, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123(5):803–10.PubMedPubMedCentralCrossRef Murahashi S, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123(5):803–10.PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Vidal J, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27(10):2890–8.PubMedCrossRef Vidal J, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27(10):2890–8.PubMedCrossRef
74.
Zurück zum Zitat Kotaka M, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40(4_suppl):9.CrossRef Kotaka M, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40(4_suppl):9.CrossRef
75.
Zurück zum Zitat Bach SP, et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? J Clin Oncol. 2022;40(16_suppl):3502–3502.CrossRef Bach SP, et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? J Clin Oncol. 2022;40(16_suppl):3502–3502.CrossRef
76.
Zurück zum Zitat Hearn N, et al. Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: a systematic review and meta-analysis of modern treatment approaches and outcomes. Clin Oncol. 2021;33(1):e1–e14.CrossRef Hearn N, et al. Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: a systematic review and meta-analysis of modern treatment approaches and outcomes. Clin Oncol. 2021;33(1):e1–e14.CrossRef
77.
78.
Zurück zum Zitat André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.PubMedCrossRef André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.PubMedCrossRef
79.
Zurück zum Zitat Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef Overmann MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.CrossRef
80.
Zurück zum Zitat Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef Cercek A, et al. PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Eng J Med. 2022;386:2363–76.CrossRef
Metadaten
Titel
Total neoadjuvant therapy in rectal cancer
verfasst von
Dr. Gudrun Piringer, MSc
Prim. Univ.-Doz. Dr. Alexander De Vries
Publikationsdatum
30.11.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00854-1

Weitere Artikel der Ausgabe 1/2023

memo - Magazine of European Medical Oncology 1/2023 Zur Ausgabe